z-logo
Premium
DBA/2‐like minor histocompatibility antigens on a BALB/c lymphoma. A balb/c anti‐DBA/2 serum which lyses the tumor and blocks balb/c anti‐tumor and anti‐DBA/2 effectors
Author(s) -
Ballinari Dario,
Grazioli Laura,
Sensi Maria Luisa,
Parmiani Giorgio,
Borrello Maria Grazia
Publication year - 1985
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910360516
Subject(s) - antigen , cytotoxic t cell , ctl* , balb/c , antiserum , minor histocompatibility antigen , pan t antigens , histocompatibility , cytotoxicity , microbiology and biotechnology , biology , immunology , lymphoma , major histocompatibility complex , virology , human leukocyte antigen , immune system , cd8 , in vitro , biochemistry
We have previously shown that BALB/c anti‐DBA/2 T cells can lyse the Moloney virus‐induced BALB/c lymphoma YC8. In order to determine whether serologically defined minor histocompatibility antigens (MiHA) cross‐reacting with those of DBA/2 tissues are present on YC8, we produced an antiserum directed against non‐H‐2 antigens by immunizing BALB/c mice with DBA/2 Con A and lipopolysaccharide (LPS)‐induced lymphoblasts. In a direct complement‐dependent cytotoxicity assay, the antiserum (OR‐I) lysed DBA/2 and YC8 but not BALB/c lymphocytes and blasts. No reactions against viral antigens were detected in the antisera as shown by the lack of cytotoxicity on a panel of lymphomas expressing a variety of viral antigens. In addition, OR‐I was able to specifically block a cytotoxic T lymphocyte (CTL), H‐2‐restricted BALB/c anti‐DBA/2 cytotoxic response when bound to DBA/2 or to YC8 target cells. These results indicate that antigens cross‐reacting between YC8 lymphoma and DBA/2 tissues are serologically defined MiHA of DBA/2 background and that OR‐I serum can block a CTL reaction by binding to target antigen rather than to major histocompatibility complex products.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here